Evidence map›Paper›PMID 21726829›Full record

ArticleCell stem cell2011

The MSC: an injury drugstore.

Arnold I Caplan, Diego Correa

5 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 830 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
830citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04711551 recruitingnot on this mapstarted 2018, after this paper: background citation

Patients-reported Outcome Measures (PROMs), Clinical Objective and Biomolecular Assessment for the Monitoring of Patients Undergoing Regenerative Medicine Treatments with Orthobiologics

TypeobservationalSponsorI.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioRan2018 to 2030Enrolled2,000ConditionsMusculoskeletal System DiseaseArmsPRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices
NCT05154591 phase1 / phase2completednot on this mapstarted 2018, after this paper: background citation

Chronic Kidney Disease of Unknown Cause (CKDu) Treated With Directed Local Intra-arterial Infusion of Autologous Stromal Vascular Fraction (SVF) Cells.

TypeinterventionalSponsorSamuel Vilchez, PhDRan2018 to 2021Enrolled18ConditionsChronic Renal Failure of Unknown CauseArmsAdipose-derived stromal vascular fraction cells
NCT06040957 narecruitingnot on this mapstarted 2024, after this paper: background citation

Bone Marrow vs Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis: Randomized Clinical Trial

TypeinterventionalSponsorIstituto Ortopedico RizzoliRan2024 to 2027Enrolled204ConditionsKnee OsteoarthritisArmsBone marrow aspirate concentrate injection, intra-articular injection of Minimally manipulated adipose tissue
NCT06304623 phase1completednot on this mapstarted 2020, after this paper: background citation

The Role of Cellular Therapy With SVF Cells (Stromal Vascular Fraction) of Adipose Tissue Origin in the Treatment of Pulmonary Fibrosis Post COVD-19

TypeinterventionalSponsorMichael H CarstensRan2020 to 2024Enrolled40ConditionsPulmonary FibrosisArmsAutologous adipose-derived SVF IV administration
NCT06373809 early_phase1completednot on this mapstarted 2021, after this paper: background citation

Diabetic Foot: Treatment of Chronic Ulcers and Neuropathy With Transplantation of Placenta Derived Stem Cells (PDSC) - A Dose Escalation Safety and Exploratory Efficacy Study

TypeinterventionalSponsorMichael H CarstensRan2021 to 2024Enrolled20ConditionsDiabetic Foot, Diabetic Neuropathies, Diabetic Foot UlcerArmsTransplantation of Placenta Derived Stem Cells
3 · Its place in the literature

Who cites it

830 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

770 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Arnold I CaplanSkeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, OH 44106-7080, USA. arnold.caplan@case.edu
Diego Correa

Funding

Total Joint ResurfacingP01AR053622 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · PI CAPLAN, ARNOLD IRWIN · 2008 to 2012
$6.0M
NIAMS NIH HHS P01 AR053622NIAMS NIH HHS P01-AR053622
6 · The paper itself

Abstract

Now that mesenchymal stem cells (MSCs) have been shown to be perivascular in vivo, the existing traditional view that focuses on the multipotent differentiation capacity of these cells should be expanded to include their equally interesting role as cellular modulators that brings them into a broader therapeutic scenario. We discuss existing evidence that leads us to propose that during local injury, MSCs are released from their perivascular location, become activated, and establish a regenerative microenvironment by secreting bioactive molecules and regulating the local immune response. These trophic and immunomodulatory activities suggest that MSCs may serve as site-regulated "drugstores" in vivo.

Indexed as

Cell- and Tissue-Based TherapyAnimalsClinical Trials as TopicHumansMesenchymal Stem CellsModels, AnimalPericytesTreatment Outcome

Identifiers

PMID21726829
PMCPMC3144500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.